- Home
- ABL vs ANAB Comparison
ABL vs ANAB Comparison
Compare ABL & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- ANAB
- Stock Information
- Founded
- ABL 2004
- ANAB 2005
- Country
- ABL United States
- ANAB United States
- Employees
- ABL N/A
- ANAB N/A
- Industry
- ABL Investment Managers
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- ABL Finance
- ANAB Health Care
- Exchange
- ABL Nasdaq
- ANAB Nasdaq
- Market Cap
- ABL 714.2M
- ANAB 759.5M
- IPO Year
- ABL N/A
- ANAB 2017
- Fundamental
- Price
- ABL $7.33
- ANAB $18.40
- Analyst Decision
- ABL Strong Buy
- ANAB Buy
- Analyst Count
- ABL 4
- ANAB 10
- Target Price
- ABL $13.88
- ANAB $36.38
- AVG Volume (30 Days)
- ABL 286.2K
- ANAB 907.9K
- Earning Date
- ABL 03-27-2025
- ANAB 05-08-2025
- Dividend Yield
- ABL N/A
- ANAB N/A
- EPS Growth
- ABL N/A
- ANAB N/A
- EPS
- ABL N/A
- ANAB N/A
- Revenue
- ABL $111,923,786.00
- ANAB $91,280,000.00
- Revenue This Year
- ABL $64.51
- ANAB N/A
- Revenue Next Year
- ABL $67.47
- ANAB $59.43
- P/E Ratio
- ABL N/A
- ANAB N/A
- Revenue Growth
- ABL 68.56
- ANAB 432.03
- 52 Week Low
- ABL $6.75
- ANAB $12.21
- 52 Week High
- ABL $12.50
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- ABL 46.01
- ANAB 55.72
- Support Level
- ABL $7.20
- ANAB $17.50
- Resistance Level
- ABL $8.70
- ANAB $19.60
- Average True Range (ATR)
- ABL 0.49
- ANAB 1.34
- MACD
- ABL -0.01
- ANAB 0.16
- Stochastic Oscillator
- ABL 15.85
- ANAB 57.04
About ABL Abacus Life Inc.
Abacus Global Management Inc, formerly Abacus Life Inc is a vertically integrated alternative asset manager specializing in investing in life insurance products throughout the lifecycle of a life insurance policy.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).